Proactive Investors
09 Jul 2026, 07:50 UTC · 2h ago
AstraZeneca's £19bn blow as Wainua heart drug fails key late-stage trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
09 Jul 2026, 07:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AstraZeneca's Wainua drug failed its Phase III CARDIO-TTRansform trial for heart disease, missing its primary endpoint of reducing cardiovascular deaths and recurrent events. — The failure of a high-profile Phase III trial removes a major potential revenue stream and led to an immediate 9.55% drop in share price.
-0.80The trial failure may lead investors to reassess the risk and probability of success for two other upcoming Phase III readouts: SERENA-4 (breast cancer) and AVANZAR (lung cancer). — Negative trial results often create a 'read-across' effect where the market lowers confidence in a company's broader R&D pipeline.
-0.40Citi had modeled peak sales for Wainua in ATTR-CM at approximately $6.2 billion. — This quantifies the significant loss of projected future cash flow resulting from the trial failure.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Wainua remains approved in over 20 countries for the polyneuropathy of hereditary transthyretin-mediated amyloidosis, an indication unaffected by the trial failure. — This provides a slight floor to the negative news by confirming that existing revenue from other indications is preserved.
+0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Market Watch
23m ago
